Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up – Here’s Why

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $11.34, but opened at $11.97. Bayer Aktiengesellschaft shares last traded at $11.96, with a volume of 152,149 shares.

Analysts Set New Price Targets

A number of research firms have weighed in on BAYRY. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Finally, Zacks Research downgraded shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The stock has a 50 day moving average price of $9.70 and a two-hundred day moving average price of $8.60. The company has a market capitalization of $45.35 billion, a price-to-earnings ratio of -134.49, a price-to-earnings-growth ratio of 5.70 and a beta of 0.66. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.